Register entry

Melinta Therapeutics, LLC

Registered sites
0
Drug products
11
Live patents
8
Countries
0
Base
Unknown
Sites

Facilities

0

No registered facilities

This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.

Exclusivity

Patents

8

Unexpired Orange Book patents where this company is the application holder.

ProductActive ingredientExpiry
KIMYRSAORITAVANCIN DIPHOSPHATEAug 2029
KIMYRSAORITAVANCIN DIPHOSPHATEApr 2030
KIMYRSAORITAVANCIN DIPHOSPHATEJul 2035
ORBACTIVORITAVANCIN DIPHOSPHATEAug 2029
ORBACTIVORITAVANCIN DIPHOSPHATEApr 2030
ORBACTIVORITAVANCIN DIPHOSPHATEJul 2035
Catalogue

Marketed products

11

Showing 11 of 11.

BrandGeneric nameFormCategory
Baxdeladelafloxacin meglumineTABLETNDA
Baxdeladelafloxacin meglumineINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONNDA
Kimyrsaoritavancin diphosphateINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONNDA
Minocinminocycline hydrochlorideINJECTIONNDA
OrbactivoritavancinINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONNDA
REZZAYOrezafunginINJECTION, POWDER, LYOPHILIZED, FOR SOLUTIONNDA
TOPROL XLMetoprolol SuccinateTABLET, EXTENDED RELEASENDA
TOPROL XLMetoprolol SuccinateTABLET, EXTENDED RELEASENDA
TOPROL XLMetoprolol SuccinateTABLET, EXTENDED RELEASENDA
TOPROL XLMetoprolol SuccinateTABLET, EXTENDED RELEASENDA
VABOMEREMeropenem-VaborbactamINJECTION, POWDER, FOR SOLUTIONNDA
Provenance

Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.